ENDOTHELIAL DYSFUNCTION CORRECTION IN PATIENTS WITH HYPERTENSION, DYSLIPIDAEMIA, AND DECREASED THYROID FUNCTION
DOI:
https://doi.org/10.61751/ijmmr.2413-6077.2023.1.24Keywords:
blood pressure, lipid metabolism, hypothyroidism, ezetimibe, vasodilation, L-arginine, thyroid stimulating hormoneAbstract
Endothelial dysfunction is considered a universal predictor of numerous diseases, development of the complications and their adverse course. The study aimed to investigate the endothelium-dependent vasodilation among patients with arterial hypertension, dyslipidemia and different functional state of the thyroid gland and feasibilities of its correction by means of hypolipidaemic and metabolic therapy. 99 patients with arterial hypertension and dyslipidemia were examined, among them were 65 hypothyroid persons (group 1) and 34 individuals with normal thyroid function (group 2). The effects of lipid-lowering combination therapy with ezetimibe and rosuvastatin or monotherapy with statins, and metabolic therapy with L-arginine aspartate during 3 months on endothelium-dependent vasodilation were studied. At the beginning of the study, the values of endothelial-dependent vasodilation in group 1 compared to those in group 2 were reliably smaller by 9.38%. After 3 months of treatment, this indicator in group 1 reliably increased by 11.11%, while 19 (29.23%) patients showed its normalization. The best values of the endothelium-dependent vasodilation was demonstrated by examinees in group 2 – the indicator reliably increased by 15.76 %, while 17 (50%) patients showed its normalization. Together, the greater increase in the percentage of endothelium – dependent vasodilation was observed among subgroups of patients that in complex treatment received combination hypolipidaemic therapy with ezetimibe and rosuvastatin, and metabolic therapy with L-arginine. The best indicators of endothelium-dependent vasodilation were demonstrated by examinees of both groups who, in addition to combination hypolipidaemic therapy, received metabolic therapy. Decreased thyroid gland function negatively affected the values of endothelium-dependent vasodilation and overweighted the possibilities of endothelial dysfunction correction in this cohort of patients. The results of the study can be applied in internal medicine clinic for complex treatment of comorbid hypertensive and hypothyroid patients.
Received: 15.02.2023 | Revised: 01.05.2023 | Accepted: 30.05.2023
References
Koval SM, Mysnychenko OV. Arterial hypertension and cerebrovascular diseases: Epidemiological, clinical, therapeutic and preventive aspects (a review of the literature and current recommendations). Hypertension. 2020;13(1):10–19. DOI: 10.22141/2224-1485.13.1.2020.197889
Charchar FJ, Prestes PR, Mills C, Ching SM, Neupane D, Marques FZ, et al. Lifestyle management of hypertension: International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension. J Hypertens. 2024;42(1):23–49. DOI: 10.1097/HJH.0000000000003563
GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1923–94. DOI: 10.1016/S0140-6736(18)32225-6
Poliakova D. Equator: Contemporary and future management of cardiovascular risk factors. Ukr Med J. 2023; 1(153):3–6. DOI: 10.32471/umj.1680-3051.153.238822
Hypertension Ukraine 2020 country profile [document on the Internet]. World Health Organization; 2021 [cited 2023 Dec 5]. Available from: https://www.who.int/publications/m/item/hypertension-ukr-country-profile-ukraine-2020
STEPS: Prevalence of non-communicable disease risk factors in Ukraine, 2019. Copenhagen: WHO Regional Office for Europe; 2020. Available from: https://apps.who.int/iris/handle/10665/336642
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334–57. DOI: 10.1161/HYPERTENSIONAHA.120.15026
Mishchenko LA, Ovdienko TM, Matova OO, Talaieva TV, Tretyak IV, Vasilinchuk NM, Vavilova LL. Functional state of endothelium and additional possibilities of its correction with the use of ethylmethylhydroxypyridine succinate in patients with arterial hypertension. Ukr Med J. 2021;4(144):2–5. DOI: 10.32471/umj.1680-3051.144.213876
Li Y, Srivastava AK, Anand-Srivastava MB. Nitric oxide and cardiovascular health. In: Ray A, Gulati K, editors. Nitric Oxide: From Research to Therapeutics. Advances in Biochemistry in Health and Disease, Volume 22. Springer, Cham; 2023. P. 15–39. DOI: 10.1007/978-3-031-24778-1_2
Smiyan S, Koshak B, Bilukha A, Koshak D. The role of endothelial dysfunction in the development of arterial hypertension in patients with ankylosing spondylarthritis. Bull Soc Hyg Health Prot Org Ukraine. 2018; 2(76):54–58. DOI: 10.11603/1681-2786.2018.2.9371
Goodwin, J. Endothelial dysfunction and vascular remodelling in hypertension. In: Flynn JT, Ingelfinger JR, Brady TM, editors. Paediatric Hypertension. Springer; 2023. P. 195–15. DOI: 10.1007/978-3-031-06231-5_41
da Silva DVT, Baião DdS, Almeida CC, Paschoalin VMF. A critical review on vasoactive nutrients for the management of endothelial dysfunction and arterial stiffness in individuals under cardiovascular risk. Nutrients. 2023; 15(11):e2618. DOI: 10.3390/nu15112618
Ministry of health of Ukraine. On approval and implementation of medical-technological documents for standardization of medical care in arterial hypertension [Internet]. 2012 [cited 2023 Dec 5]. Order No 384/2012. 2012 May 24. Available from: https://zakon.rada.gov.ua/rada/show/v0384282-12#Text
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953–41. DOI: 10.1097/HJH.0000000000001940
Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS, Strasser T. Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull World Health Organ. 1970;43(6):891–15.
Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340(8828):1111–15. DOI: 10.1016/0140-6736(92)93147-f
The World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects [Internet]. Available from: https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/
Serhiyenko V, Serhiyenko A. Diabetes, dyslipoproteinemia and statins. Endokrynologia. 2021;27(1):29–42. DOI: 10.31793/1680-1466.2021.27-1.29
German CA, Liao JK. Understanding the molecular mechanisms of statin pleiotropic effects. Arch Toxicol. 2023;97:1529–45. DOI: 10.1007/s00204-023-03492-6
Higashi Y. Endothelial function in dyslipidemia: Roles of LDL-cholesterol, HDL-cholesterol, and triglycerides. Cells. 2023;12(9):e1293. DOI: 10.3390/cells12091293
Di Costanzo A, Indolfi C, Sorrentino S, Esposito G, Spaccarotella CAM. The effects of statins, ezetimibe, PCSK9-inhibitors, inclisiran, and icosapent ethyl on platelet function. Int J Mol Sci. 2023;24(14):e11739. DOI: 10.3390/ijms241411739
Vavlukis M, Vavlukis A. Adding ezetimibe to statin therapy: Latest evidence and clinical implications. Drugs Context. 2018:7:e212534. DOI: 10.7573/dic.212534
Serhiyenko V, Serhiyenko A. Ezetimibe and diabetes mellitus: A new strategy for lowering cholesterol. Int J Endocrinol. 2022;18(5):302–14. DOI: 10.22141/2224-0721.18.5.2022.1190
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–23. DOI: 10.1093/eurheartj/ehz486
Szlas A, Kurek JM, Krejpcio Z. The potential of l-arginine in prevention and treatment of disturbed carbohydrate and lipid metabolism – a review. Nutrients. 2022;14(5):961. DOI: 10.3390/nu14050961
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Marta Orel, Larysa Martynyuk
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
